Tenaya Therapeutics, Inc. (TNYA) Stock Analysis & Investment Frameworks

Tenaya Therapeutics, Inc. (TNYA) stock analysis on Invetso. Review Tenaya Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Tenaya Therapeutics, Inc. Company Overview

Tenaya Therapeutics, Inc. Key Financial Metrics

About Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Tenaya Therapeutics, Inc. Investment Frameworks

Invetso analyzes Tenaya Therapeutics, Inc. (TNYA) across the following frameworks:

Explore More TNYA Research